Archive · 7 Nov 2025
Obesity Drugs Mounjaro and Wegovy Lead Indian Market Amidst Global Attention
Some new medicines for weight loss and diabetes, like Mounjaro and Wegovy, are becoming very popular in India and around the world.
In October, Mounjaro made the most money in India among all medicines.
This is because it helps people lose a lot of weight, and the companies are selling it at a good price in India.
Even though other medicines like Augmentin sell more in terms of quantity, the new weight-loss drugs are bringing in more money.
Soon, when patents expire, cheaper versions of these medicines will be available.
These companies also agreed to lower prices for their medicines in the United States.
Doctors recommend these medicines because many people in India have problems with obesity and diabetes.
Eli Lilly's Mounjaro became the top-selling drug by value in India in October, generating significant revenue since its March 2025 launch.
Novo Nordisk's anti-obesity and diabetes drugs, Wegovy and Rybelsus, also recorded substantial sales in the Indian market.
While Mounjaro led in sales value, established drugs like Augmentin continue to lead in sales volume.
Multinational companies are implementing 'smart' pricing for these innovative treatments in India, and generic versions are expected after patent expiries.
US President Trump announced agreements with Eli Lilly and Novo Nordisk to significantly reduce the monthly prices of Mounjaro and Ozempic/Wegovy in the United States.
- Who
- Eli Lilly (Mounjaro), Novo Nordisk (Wegovy, Rybelsus), GlaxoSmithKline (Augmentin)
- What
- Anti-obesity and diabetes drugs from multinational companies are leading the market in India and gaining global attention, with Mounjaro topping sales value in India for October. Agreements were made to lower prices in the US.
- When
- October (Mounjaro's top sales), March 2025 (Mounjaro launch), Next March (Patent expiry for semaglutide), This week (US White House meeting), November 7, 2025 (Publication date)
- Where
- India, Global (US, Western world)
- Why
- High efficacy for obesity and diabetes, 'smart' pricing strategies for the Indian market, and growing global demand for these treatments.
Mounjaro's Market Dominance
Established Brands' Volume Leadership
Sales Performance
Mounjaro's Market Dominance
Eli Lilly's Mounjaro achieved top sales value in India for October, driven by its weight-loss and diabetes treatment benefits, and a 'smart' pricing strategy for the Indian market. Novo Nordisk's Wegovy and Rybelsus also showed significant sales in the same categories.
Established Brands' Volume Leadership
Despite Mounjaro's value leadership, GlaxoSmithKline's antibiotic Augmentin and Glycomet GP retained their positions as top sellers in terms of volume for the 12 months ending October. Rybelsus sales have plateaued after an initial surge.
Market Drivers
Mounjaro's Market Dominance
The growth of Mounjaro and Wegovy is attributed to their effectiveness in treating obesity and diabetes-induced obesity, conditions prevalent in India. Multinational companies have adopted 'smart' pricing for these innovative products.
Established Brands' Volume Leadership
Established drugs like Augmentin and Glycomet GP maintain their sales volume due to consistent demand and long-standing presence in the market, serving critical health needs.
- Top Selling Drug (October, India - Value)
- Eli Lilly's Mounjaro
- Mounjaro Sales (India, Since Launch)
- ₹333 crore
- Wegovy Sales (India, October)
- ₹9 crore
- Rybelsus Sales (India, October)
- ₹26 crore
- Top Selling Drugs (12 Months to Oct - Volume)
- Augmentin, Glycomet GP
- US Pricing Agreement (Mounjaro, Ozempic/Wegovy)
- Drop from ~$1,000/month to $300-odd
Sources
$11.38 million sales in Oct: Eli Lilly’s obesity drug Mounjaro top selling drug by value in India
Eli Lilly’s Mounjaro becomes India’s top selling drug by value in October
Eli Lilly's weight loss drug Mounjaro becomes top selling medicine in India by value in October
Mounjaro gains weight, tops India’s drug charts with ₹100 crore sales in October
Eli Lilly’s Anti-Obesity Drug Mounjaro Becomes India’s Top-Selling Medicine in October; Here’s Why
